Keymed Biosciences (HKEX: 02162) reported total revenue of RMB617 million for the six months ended June 30, 2026, in results published on Aug. 19. Its flagship product, Kangyueda, generated RMB393 million, up 132% from a year earlier, supported by a commercial team of nearly 500 people covering more than 1,600 hospitals. Collaboration revenue reached RMB224 million, mainly from milestone payments by AstraZeneca. Profit for the period was RMB122 million, marking a return to profitability after a loss, while cash reserves stood at RMB3.24 billion. Kangyueda was added to China’s national essential medicines list in July, effective Sept. 1, supporting expansion into county-level and primary healthcare markets. The company also reported progress across its pipeline, including regulatory submissions for Stapokibart, late-stage development of CMG901/AZD0901 and CM512, and a strategic transaction involving CM336 that provided an upfront payment of $257 million and potential additional milestone payments of up to $70 million. Keymed operates six integrated platforms and has 21,800 liters of production capacity in Chengdu, with additional 24,000-liter stainless-steel production lines expected soon. As of June 30, it had 1,768 full-time employees, including 500 in commercial operations and 420 in research and development and clinical trials.